Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers

10/15/2021 | 08:07am EST

By Colin Kellaher

Merck & Co. and Eisai Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of the combination of Eisai's Lenvima and Merck's Keytruda in two new cancer indications.

Merck, based in Kenilworth, N.J., and Tokyo-based Eisai said the CHMP recommended approval of the combination as a first-line treatment of adults with advanced renal cell carcinoma.

The committee also backed the combination for adults with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and aren't candidates for curative surgery or radiation advanced endometrial carcinoma.

The European Commission, which generally follows the CHMP's advice, will now review the recommendations, with decisions expected by the end of the year.

Eisai and Merck in March 2018 formed a collaboration to jointly develop, manufacture and commercialize Lenvima as monotherapy and in combination with Merck's blockbuster cancer drug Keytruda.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-15-21 0806ET

Stocks mentioned in the article
ChangeLast1st jan.
EISAI CO., LTD. 0.58% 6926 End-of-day quote.-6.05%
MERCK & CO., INC. 0.79% 72.86 Delayed Quote.-11.64%
All news about MERCK & CO., INC.
11:49aGLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta...
04:28aMerck Prices $8 Billion Senior Notes Offering
MT
04:17aLytix Biopharma Starts Treatment of First Patient in Mid-Stage Trial for Tumor Drug
MT
12/07Merck & Co. Allocates Additional $150 Million For Global Maternal Health Program
MT
12/07Merck Prices $8.0 Billion Debt Offering
BU
12/07Merck Announces Five-Part US Dollar Issuance With Maturities From 5-40 Years
MT
12/07Guggenheim Downgrades Merck to Neutral From Buy
MT
12/07Merck Pledges Additional $150 Million to End Maternal Mortality Inequities
MT
12/07Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality..
BU
12/07NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 ..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 576 M - -
Net income 2021 12 378 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 14,9x
Yield 2021 3,59%
Capitalization 183 B 183 B -
EV / Sales 2021 4,18x
EV / Sales 2022 3,50x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 72,28 $
Average target price 95,11 $
Spread / Average Target 31,6%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-11.64%182 575
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215